Lithium Price Watch: What the Forward Curve Is Telling Buyers Right Now

BMI's latest lithium carbonate, lithium hydroxide and spodumene data shows where price risk is concentrated across the next 12 months, and what that means for procurement, offtake and hedging decisions.

Key takeaways

• As of 10 August 2026, BMI assesses lithium carbonate (CIF Asia, spot, mid-point) at $18,160/t, lithium hydroxide (CIF Asia, spot, mid-point) at $18,510/t, and 6% spodumene concentrate (FOB Australia, mid-point) at $2,000/t.

• BMI's July 2026 Lithium Price Risk Monitor puts lithium hydroxide spot Value at Risk (VaR) at $1,434/t at 99% confidence over 10 trading days, equal to $14.3 million of exposure on a 10,000-tonne position.

• Risk is concentrated differently across the curve. Lithium hydroxide VaR peaks at six months at $1,695/t ($17.0 million), while lithium carbonate VaR reaches $1,781/t ($17.8 million) at three months and remains at that level through 12 months.

• Between June and July, BMI's forward curves moved most sharply across the three-to-12-month tenors, with forward prices in that range rising by $850-$2,787/t depending on instrument and tenor.

• Since end-July, lithium carbonate has fallen 5.7%, while lithium hydroxide has moved less than 1%. That realised divergence is consistent with the broader risk picture in BMI's July data, although VaR measures potential loss magnitude rather than price direction.

For automotive and battery procurement teams, the question is no longer simply whether lithium prices are volatile. The more useful questions are where that risk sits on the curve, how large the exposure is, and which tenors matter most for real procurement decisions.

BMI's July 2026 data shows that the answer differs materially by product. Lithium hydroxide risk is concentrated around the six-month tenor, while lithium carbonate reaches an elevated risk plateau from three months through one year. Those are also the parts of the forward curve that repriced most sharply month-on-month.

For buyers deciding whether to lock in exposure or remain floating, that combination matters. The three-to-12-month window now carries both higher forward pricing and elevated measured price risk, making it the part of the curve procurement and treasury teams need to scrutinise most closely.

What are lithium carbonate, lithium hydroxide and spodumene prices today?

As of 10 August 2026, BMI assesses lithium carbonate at $18,160/t, lithium hydroxide at $18,510/t and 6% spodumene concentrate at $2,000/t on the specified physical market bases below.

Benchmark Mineral Intelligence (BMI) is an IOSCO-compliant price reporting agency (PRA) and a registered Benchmark Administrator under the UK Benchmarks Regulation, regulated by the Financial Conduct Authority.

These are BMI's daily spot assessments, published as part of the Benchmark Terminal's lithium price series. Each figure should be read together with its grade, geography and delivery basis rather than as a universal lithium price.

How much does lithium price volatility cost a buyer?

On a 10,000-tonne annual position, BMI's July 2026 data puts 10-day, 99% VaR at $14.3 million for lithium hydroxide, $13.7 million for lithium carbonate and $1.6 million for spodumene at spot.

Value at Risk estimates a loss threshold that a position would not be expected to exceed over a specified period at a given confidence level, subject to the model assumptions. It converts a broad concept such as 'volatility' into a specific measure of financial exposure that procurement and treasury teams can compare across products and tenors.

BMI's July 2026 Lithium Price Risk Monitor calculates lithium hydroxide spot VaR at $1,434/t, or $14.3 million on a 10,000-tonne position. Annualised volatility for lithium hydroxide is 53.0%. Lithium carbonate carries comparable spot VaR of $1,371/t ($13.7 million), with annualised volatility of 48.4%. Spodumene has a smaller dollar exposure at $165/t ($1.6 million), although its annualised volatility of 54.1% is the highest of the three.

Where is lithium price risk highest on the forward curve?

Lithium hydroxide VaR peaks at the six-month tenor, while lithium carbonate reaches its highest measured VaR at three months and remains at that level through 12 months.

The more useful finding is not the spot number in isolation, but where risk is concentrated along the curve. For lithium hydroxide, VaR rises from $1,434/t at spot to a peak of $1,695/t at six months before easing to $1,594/t at 12 months. On a 10,000-tonne position, that equates to $17.0 million of 10-day exposure at the six-month point.

Lithium carbonate has a different risk shape. VaR increases from $1,371/t at spot to $1,781/t at three months, then remains at $1,781/t through six and 12 months. That is equivalent to $17.8 million of 10-day exposure across the entire three-to-12-month window.

For procurement teams, those are different risk profiles and therefore different hedging conversations. A six-month hydroxide exposure sits at the point of maximum measured VaR, whereas carbonate exposure remains elevated across a much broader part of the forward curve.

How has the lithium forward curve changed for buyers negotiating offtake agreements?

Between June and July 2026, BMI's lithium forward curves repriced most sharply across the three-to-12-month tenors, with forward prices in that range moving higher by $850-$2,787/t depending on instrument and tenor.

That timing matters because the three-to-12-month window is commercially relevant for many offtake and supply agreements. The repricing means buyers evaluating future exposure are no longer looking at the same forward cost structure they were a month earlier.

At the same time, spot and short-tenor spodumene prices softened over the period even as the spodumene forward curve remained in moderate contango. Near-term softness alongside firmer pricing further out suggests the market is distinguishing between current availability and future price risk rather than pricing one uniform story across the curve.

Should lithium procurement teams lock in prices now or wait?

BMI's data does not prescribe one procurement decision for every buyer, but it shows that remaining unhedged leaves exposure concentrated in the same three-to-12-month tenors that have recently repriced most sharply.

A decision to fix, float or hedge lithium exposure depends on contract structure, risk appetite, liquidity, physical supply requirements and internal treasury policy. What the data can do is make the trade-off more explicit.

For buyers deciding whether to lock in exposure or remain floating, BMI's July data shows that the three-to-12-month part of the curve now carries both higher forward pricing and elevated measured price risk. Waiting therefore leaves buyers exposed to precisely the tenors in which the market has repriced most sharply.

The implication is not that every buyer should immediately fix its entire position. It is that procurement and treasury teams should evaluate forward exposure by tenor, rather than relying on a single spot-price view or a general assumption that risk simply increases with time.

What has happened to lithium prices since the July risk reading?

Since 31 July, lithium carbonate has fallen 5.7%, lithium hydroxide has risen 0.6% and spodumene has declined 3.3%.

The realised divergence is consistent with the broader risk picture in BMI's July data: carbonate carried the more elevated forward VaR profile of the two lithium chemicals, while hydroxide's risk was more concentrated around a specific tenor. That does not mean VaR predicted which direction prices would move. VaR measures the potential magnitude of loss under the model assumptions, not directional probability.

What the subsequent move does illustrate is why product-level and tenor-level risk measures matter. Two lithium chemicals can sit at similar spot price levels while carrying different forward risk profiles and then experience materially different realised price moves.

What does this mean for procurement, treasury and offtake strategy?

Lithium price risk should be managed as a set of product- and tenor-specific exposures, not as one generic 'lithium volatility' problem.

For procurement teams, the relevant benchmark needs to match the physical exposure being purchased. For treasury teams, the relevant risk measure needs to reflect the tenor and size of that exposure. For commercial teams negotiating offtake agreements, the forward curve provides a market view of how the cost of future exposure differs from today's spot price.

Bringing those three views together creates a more useful decision framework: a physical benchmark for the underlying market, a forward curve for the future pricing window, and a risk measure that quantifies the potential financial exposure.

That is particularly important in a market where price risk is not distributed evenly. The current data shows different risk shapes for carbonate, hydroxide and spodumene, which means a single procurement rule or hedging trigger is unlikely to be appropriate across all three.

Frequently asked questions

What is the lithium carbonate price today?

As of 10 August 2026, BMI assesses the lithium carbonate price (Min 99.5%, CIF Asia, spot) at a mid-point of $18,160/t, down from $19,250/t at end-July 2026.

What is the lithium hydroxide price today?

As of 10 August 2026, BMI assesses the lithium hydroxide price (Min 56.5%, CIF Asia, spot) at a mid-point of $18,510/t, up slightly from $18,400/t at end-July 2026.

What is the spodumene price today?

As of 10 August 2026, BMI assesses the spodumene price (6% concentrate, FOB Australia) at a mid-point of $2,000/t, down from $2,069/t at end-July 2026.

What is Value at Risk (VaR) in lithium pricing?

Value at Risk estimates a loss threshold that a position would not be expected to exceed over a specified period at a given confidence level, subject to the model assumptions. BMI calculates lithium VaR at 99% confidence over a 10-trading-day horizon so procurement and treasury teams can compare potential price exposure in dollar terms.

How much lithium price risk does a 10,000-tonne position carry?

At spot, BMI's July 2026 data puts 10-day, 99% VaR at $14.3 million for a 10,000-tonne lithium hydroxide position, $13.7 million for lithium carbonate and $1.6 million for spodumene. Forward exposure varies by tenor and reaches $17.0 million for lithium hydroxide at six months and $17.8 million for lithium carbonate from three through 12 months.

Is lithium carbonate or lithium hydroxide riskier right now?

BMI's July 2026 data shows the higher forward VaR in lithium carbonate, which reaches $1,781/t from the three-month tenor through 12 months. Lithium hydroxide peaks at $1,695/t at six months. The shape of the risk is therefore different as well as the absolute level.

Which part of the lithium forward curve matters most for offtake agreements?

The relevant tenor depends on the individual contract, but the three-to-12-month window is commercially important for many offtake and supply agreements. BMI's July 2026 data shows that this is also the part of the curve where forward prices and measured risk have recently become more elevated.

Does Value at Risk predict whether lithium prices will rise or fall?

No. VaR is a measure of potential loss magnitude over a defined horizon and confidence level. It does not predict the direction of the next price move.

In summary

• BMI's data quantifies lithium price risk in specific dollar terms rather than treating volatility as a qualitative concern.

• Risk is concentrated at different tenors for different lithium products: six months for hydroxide and a three-to-12-month plateau for carbonate.

• The forward curve has repriced the same commercially relevant tenors in which measured risk is elevated.

• Spot moves since end-July show why product-specific risk analysis matters: carbonate, hydroxide and spodumene have not moved in lockstep.

• For procurement and treasury teams, the practical implication is to match the physical benchmark, forward tenor and risk measure to the actual exposure being managed.

Methodology note

VaR figures are parametric: price x (annualised volatility x 2.326 x square root of 10), calculated from 293 daily BMI spot price changes per instrument and applied to BMI's forward price at each tenor. Figures are shown at 99% confidence over a 10-trading-day horizon on a 10,000-tonne annual offtake position.

BMI's forward curve reflects PRA-governed monthly marks launched in Q1 2026. Spot figures are BMI daily mid-point assessments: lithium carbonate and lithium hydroxide are CIF Asia (spot), while spodumene is FOB Australia, 6% concentrate. Full tenor-by-tenor VaR tables, forward curve data and BMI's correlation analysis across the broader lithium, cobalt, cathode and cell complex are available via the Benchmark Terminal.